Drugs / FP002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05982080 | Aug 2023 → Apr 2025 overdue | neoplastic disease or syndrome | Guangdong Fapon Biopharma Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-02-22 | Fapon Biotherapy Inc. | Regulatory 菲鹏制药创新CD47单抗新药FP002临床试验在美国获批 fapon.com ↗
FP002是菲鹏制药第一个中美双报的临床项目，本项目获得美国FDA临床试验批准是公司在创新药研发上的重要里程碑。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-02-22 | Fapon Biotherapy Inc. | 菲鹏制药创新CD47单抗新药FP002临床试验在美国获批 fapon.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05982080 ↗ |
| Route | Intravenous | “administered intravenously” NCT05982080 ↗ |